Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. (Q51865097)

14 April 2018

title

Additive effects of a cholinesterase inhibitor and a histamine inverse agonist on scopolamine deficits in humans. (English)

1 reference

14 April 2018

author

Paul Maruff

2

1 reference

14 April 2018

author name string

William Cho

1

1 reference

14 April 2018

John Connell

3

1 reference

14 April 2018

Cindy Gargano

4

1 reference

14 April 2018

Nicole Calder

5

1 reference

14 April 2018

Scott Doran

6

1 reference

14 April 2018

Sabrina Fox-Bosetti

7

1 reference

14 April 2018

Aizza Hassan

8

1 reference

14 April 2018

John Renger

9

1 reference

14 April 2018

Gary Herman

10

1 reference

14 April 2018

Christopher Lines

11

1 reference

14 April 2018

Ajay Verma

12

1 reference

14 April 2018

publication date

7 June 2011

1 reference

14 April 2018

number of pages

12

1 reference

based on heuristic

inferred from page(s)

published in

Psychopharmacology

1 reference

14 April 2018

volume

218

1 reference

14 April 2018

issue

3

1 reference

14 April 2018

page(s)

513-524

1 reference

14 April 2018

The role of histamine on cognition

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Characterization of histamine H3 receptors regulating acetylcholine release in rat entorhinal cortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Constitutive activity of the histamine H3 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Interactions between histaminergic and cholinergic systems in learning and memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: effects on cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Acetylcholine, histamine, and cognition: two sides of the same coin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Cognitive testing in early phase clinical trials: outcome according to adverse event profile in a Phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Cognitive testing in early-phase clinical trials: development of a rapid computerized test battery and application in a simulated Phase I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Differentiating the effects of centrally acting drugs on arousal and memory: an event-related potential study of scopolamine, lorazepam and diphenhydramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Pharmacokinetics and pharmacodynamics of scopolamine after subcutaneous administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Separate and combined effects of scopolamine and nicotine on retrieval-induced forgetting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

The histamine H3 receptor: an attractive target for the treatment of cognitive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Practice effects associated with the repeated assessment of cognitive function using the CogState battery at 10-minute, one week and one month test-retest intervals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Histamine function in brain disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

The use of effect sizes to characterize the nature of cognitive change in psychopharmacological studies: an example with scopolamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

The role of histamine and the tuberomamillary nucleus in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Cholinergic 'blockade' as a model for cholinergic depletion. A comparison of the memory deficits with those of Alzheimer-type dementia and the alcoholic Korsakoff syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Synthesis and evaluation of structurally constrained quinazolinone derivatives as potent and selective histamine H3 receptor inverse agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Histamine H(3)-receptor antagonism improves memory retention and reverses the cognitive deficit induced by scopolamine in a two-trial place recognition task.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Histamine and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Central histaminergic system and cognition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Histamine H3 receptor-mediated impairment of contextual fear conditioning and in-vivo inhibition of cholinergic transmission in the rat basolateral amygdala

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

An examination of the construct validity and factor structure of the Groton Maze Learning Test, a new measure of spatial working memory, learning efficiency, and error monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Donepezil: a clinical review of current and emerging indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Histamine H3 receptor antagonists go to clinics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Developmental origins of the age-related decline in cortical cholinergic function and associated cognitive abilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Reversal of scopolamine-induced deficits with a single dose of donepezil, an acetylcholinesterase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

A method for determining the magnitude of change across different cognitive functions in clinical trials: the effects of acute administration of two different doses alprazolam

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Histamine H3 antagonists as wake-promoting and pro-cognitive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Specific impairments in visuospatial working and short-term memory following low-dose scopolamine challenge in healthy older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Cognitive domains affected by histamine H(1)-antagonism in humans: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2344-Y

Pharmacokinetics of E2020, a new compound for Alzheimer's disease, in healthy male volunteers.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21644059

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21644059

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00213-011-2344-Y

1 reference

14 April 2018

1 reference

14 April 2018